LNDC Landec Corp.

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum.

Details regarding Lifecore’s participation are as follows:

  • 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

    Details: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in investor meetings

    Conference Dates: March 17 – 18, 2026

    Fireside Chat Time/Date: 9:00am – 9:35am Eastern Time on Tuesday, March 17, 2026, webcast available

    Location: Virtual

A webcast of the fireside chat may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: . Additionally, a replay of the webcast will be available on the Lifecore website following the conference. 

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: ) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at .

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners

Stephanie Diaz (Investors & Media)

415-675-7401

Ryan D. Lake (CFO)

Lifecore Biomedical

952-368-6244



EN
10/03/2026

Underlying

LNDCLandec Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 18,500 shares of its common stock under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopha...

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer -- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore’s High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore...

March 26, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Lead...

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company -- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a CD...

March 23, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical Reports Financial Results for the Fourth Quarter a...

Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update -- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives Drive Further Improvement in Margins -- Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biome...

March 16, 2026 1 EN
 PRESS RELEASE
Free
LNDC LANDEC CORP.

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Marke...

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore’s participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat...

March 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch